[HTML][HTML] Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations
AN Habowski, DP Budagavi, SD Scherer, AB Aurora… - Cancers, 2024 - mdpi.com
Simple Summary Over the last two decades, there has been a major shift in cancer research
models. What was once dominated by genetically engineered mice models and fast-growing …
models. What was once dominated by genetically engineered mice models and fast-growing …
[HTML][HTML] Starving cancer cells to enhance DNA damage and immunotherapy response
A Shahi, D Kidane - Oncotarget, 2024 - ncbi.nlm.nih.gov
Prostate cancer (PCa) poses significant challenges in treatment, particularly when it
progresses to a metastatic, castrate-resistant state. Conventional therapies, including …
progresses to a metastatic, castrate-resistant state. Conventional therapies, including …
Cell Context is the third axis of synergy for the combination of ATR inhibition and cisplatin in Ewing sarcoma
J Jess, KM Sorensen, EA Boguslawski, MC Stout… - Clinical Cancer …, 2024 - AACR
Purpose: The importance of cellular context to the synergy of DNA damage response (DDR)-
targeted agents is important for tumors with mutations in DDR pathways, but less well …
targeted agents is important for tumors with mutations in DDR pathways, but less well …
Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition
CF Ribeiro, S Rodrigues, DC Bastos, GN Fanelli… - Science …, 2024 - science.org
Androgen deprivation therapy (ADT) is the primary treatment for prostate cancer; however,
resistance to ADT invariably develops, leading to castration-resistant prostate cancer …
resistance to ADT invariably develops, leading to castration-resistant prostate cancer …
[HTML][HTML] IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer
Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant
prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has …
prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has …
Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer
L Chen, YX Xu, YS Wang, YY Ren, YM Chen… - Journal of …, 2024 - Elsevier
ABSTRACT Ethnopharmacological relevance Traditional Chinese Medicines (TCMs) have
emerged as a promising complementary therapy in the management of prostate cancer …
emerged as a promising complementary therapy in the management of prostate cancer …
The multifaceted functions of DNA‐PKcs: implications for the therapy of human diseases
J Wu, L Song, M Lu, Q Gao, S Xu, PK Zhou, T Ma - MedComm, 2024 - Wiley Online Library
The DNA‐dependent protein kinase (DNA‐PK), catalytic subunit, also known as DNA‐PKcs,
is complexed with the heterodimer Ku70/Ku80 to form DNA‐PK holoenzyme, which is well …
is complexed with the heterodimer Ku70/Ku80 to form DNA‐PK holoenzyme, which is well …